HTBX Heat Biologics Inc.

0.45
0  1%
Previous Close 0.44
Open 0.44
Price To Book 0.92
Market Cap 15,325,739
Shares 34,140,652
Volume 160,240
Short Ratio
Av. Daily Volume 394,190
Stock charts supplied by TradingView

NewsSee all news

  1. Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

    Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 MonthsDURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), presented additional positive Phase 2 interim

  2. Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

    DURHAM, NC / ACCESSWIRE / November 18, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced

  3. Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

    Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer PatientsMORRISVILLE, NC / ACCESSWIRE / November 15, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  4. Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

    Promising results in patients whose disease has progressed after checkpoint inhibitor therapyDURHAM, NC / ACCESSWIRE / November 11, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  5. Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

    Announces Abstract Summarizing Favorable Interim Phase 2 Data of HS-110 Plus NivolumabAdditional Data to be Reported in Poster Presentation at the SITC 34th Annual Meeting on November 8, 2019DURHAM, NC / ACCESSWIRE /

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data presented at AACR November 19, 2019 noted ORR of 20% (RECIST 1.1).
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)
Phase 1 trial to be initiated 4Q 2019.
HS-130
Solid tumors

Latest News

  1. Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

    Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 MonthsDURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), presented additional positive Phase 2 interim

  2. Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

    DURHAM, NC / ACCESSWIRE / November 18, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced

  3. Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

    Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer PatientsMORRISVILLE, NC / ACCESSWIRE / November 15, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  4. Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

    Promising results in patients whose disease has progressed after checkpoint inhibitor therapyDURHAM, NC / ACCESSWIRE / November 11, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  5. Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

    Announces Abstract Summarizing Favorable Interim Phase 2 Data of HS-110 Plus NivolumabAdditional Data to be Reported in Poster Presentation at the SITC 34th Annual Meeting on November 8, 2019DURHAM, NC / ACCESSWIRE /